Pulse Biosciences (NASDAQ:PLSE) released its quarterly earnings results on Thursday. The company reported ($0.57) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.04, Fidelity Earnings reports.
NASDAQ:PLSE traded up $0.08 during mid-day trading on Friday, hitting $14.39. 63,300 shares of the company’s stock traded hands, compared to its average volume of 56,101. The firm has a 50 day moving average of $14.95 and a two-hundred day moving average of $13.25. Pulse Biosciences has a 12 month low of $9.52 and a 12 month high of $19.77. The firm has a market capitalization of $306.54 million, a price-to-earnings ratio of -6.54 and a beta of 1.84. The company has a current ratio of 12.92, a quick ratio of 12.92 and a debt-to-equity ratio of 0.07.
Several analysts have recently issued reports on PLSE shares. ValuEngine upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, October 30th. BidaskClub downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st.
Pulse Biosciences, Inc operates as a clinical stage medical therapy company. It engages in the research and development, and commercialization of CellFX system that provides a precise and non-thermal cellular treatment technology delivering nanosecond duration energy pulses that impact cells in treated tissue while sparing surrounding non-cellular tissue primarily for dermatology applications.
Recommended Story: Using other technical indicators with support levels
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.